Background
Open-label, non-inferiority phase III FLYER trial (ITT 588 patients, ages 18-60) with favorable-prognosis CD20+ aggressive B-cell NHL: stage I-II, normal LDH, ECOG 0-1, non-bulky (<7.5 cm). Radiotherapy was omitted except for testicular involvement.
Interventions and follow up
Arm A: 4 cycles R-CHOP + 2 additional doses of rituximab (n=294).
Arm B: 6 cycles R-CHOP (n=295).
R-CHOP: rituximab 375, cyclophosphamide 750, doxorubicin 50, vincristine 1.4 mg/m2 (max 2 mg) D1 + prednisone/prednisolone 100 mg D1-5, q21d.
Primary endpoint: 3-yr PFS (non-inferiority margin −5.5%).
mFollow up: 66 months.
Arm B: 6 cycles R-CHOP (n=295).
R-CHOP: rituximab 375, cyclophosphamide 750, doxorubicin 50, vincristine 1.4 mg/m2 (max 2 mg) D1 + prednisone/prednisolone 100 mg D1-5, q21d.
Primary endpoint: 3-yr PFS (non-inferiority margin −5.5%).
mFollow up: 66 months.
Results
3-yr PFS: 96% (4xR-CHOP+2R) vs 94% (6xR-CHOP) — met non-inferiority.
3-yr OS: 99% vs 98%.
Relapse/progression: 40 events, balanced between arms; ~two-thirds occurred after 2 years.
CNS relapse: none observed in either arm.
3-yr OS: 99% vs 98%.
Relapse/progression: 40 events, balanced between arms; ~two-thirds occurred after 2 years.
CNS relapse: none observed in either arm.
Adverse events
Nonhematologic (grade 3-4, Arm A vs B): infection 7.5% vs 8.3%; paresthesia 5.4% vs 4.7%.
Overall: the 4-cycle arm reduced total chemotherapy exposure by ~one-third, lowering cumulative anthracycline and vincristine-related toxicity; nonhematologic toxicities were otherwise comparable between arms.
Overall: the 4-cycle arm reduced total chemotherapy exposure by ~one-third, lowering cumulative anthracycline and vincristine-related toxicity; nonhematologic toxicities were otherwise comparable between arms.
Conclusions
In young patients with favorable-prognosis aggressive B-cell lymphoma (stage I-II, normal LDH, <7.5 cm), 4 cycles of R-CHOP plus 2 doses of rituximab is non-inferior to 6 cycles of R-CHOP, reducing toxicity without compromising outcome.
Key Limitations
Findings apply only to a narrowly defined favorable-risk young population and should not be extrapolated to bulky, older, or higher-IPI patients. Event numbers were low, and late relapses (after 2 years) underscore the need for continued follow-up.
Clinical Context
FLYER established 4xR-CHOP + 2R as a standard option for young, favorable-risk limited-stage DLBCL per ASCO/ESMO guidance, allowing de-escalation of chemotherapy exposure. It complements the GOYA and other limited-stage DLBCL data.